|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang FL and Yu SJ: Esophageal cancer:
Risk factors, genetic association, and treatment. Asian J Surg.
41:210–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaghjiani RG and Molena D: Surgical
management of esophageal cancer. Chin Clin Oncol. 6:472017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou N, Rajaram R and Hofstetter WL:
Management of locally advanced esophageal cancer. Surg Oncol Clin N
Am. 29:631–646. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Imazeki H and Kato K: Development of
chemotherapeutics for unresectable advanced esophageal cancer.
Expert Rev Anticancer Ther. 20:1083–1092. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelly RJ: Emerging multimodality
approaches to treat localized esophageal cancer. J Natl Compr Canc
Netw. 17:1009–1014. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borggreve AS, Kingma BF, Domrachev SA,
Koshkin MA, Ruurda JP, van Hillegersberg R, Takeda FR and Goense L:
Surgical treatment of esophageal cancer in the era of multimodality
management. Ann N Y Acad Sci. 1434:192–209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kakeji Y, Oshikiri T, Takiguchi G, Kanaji
S, Matsuda T, Nakamura T and snf Suzuki S: Multimodality approaches
to control esophageal cancer: Development of chemoradiotherapy,
chemotherapy, and immunotherapy. Esophagus. 18:25–32. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morimoto H, Fujiwara Y, Lee S, Amano K,
Hosono M, Miki Y and Osugi H: Treatment results of neoadjuvant
chemoradiotherapy followed by radical esophagectomy in patients
with initially inoperable thoracic esophageal cancer. Jpn J Radiol.
36:23–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eyck BM, van der Wilk BJ, Lagarde SM,
Wijnhoven BPL, Valkema R, Spaander MCW, Nuyttens JJME, van der
Gaast A and van Lanschot JJB: Neoadjuvant chemoradiotherapy for
resectable oesophageal cancer. Best Pract Res Clin Gastroenterol.
36–37. 37–44. 2018.PubMed/NCBI
|
|
11
|
Faiz Z, Kats-Ugurlu G, Mul VEM, Karrenbeld
A, Burgerhof HGM, Plukker JTM and Muijs CT: Locoregional residual
esophageal cancer after neo-adjuvant chemoradiotherapy and surgery
regarding anatomic site and radiation target fields: A
histopathologic evaluation study. Ann Surg. 275:e759–e765. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sasaki K, Uchikado Y, Omoto I, Arigami T,
Osako Y, Noda M, Okumura H, Maemura K, Higashi R, Yoshiura T and
Natsugoe S: Neoadjuvant chemoradiotherapy with docetaxel,
cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced
esophageal squamous cell carcinoma. Cancer Chemother Pharmacol.
83:581–587. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant
chemoradiotherapy followed by surgery versus surgery alone for
locally advanced squamous cell carcinoma of the esophagus
(NEOCRTEC5010): A phase III multicenter, randomized, open-label
clinical trial. J Clin Oncol. 36:2796–2803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin Q, Xu H, Liu J, Zhang C, Xu L, Di X,
Zhang X and Sun X: Does timing of esophagectomy following
neoadjuvant chemoradiation affect outcomes? A meta-analysis. Int J
Surg. 59:11–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klevebro F, Nilsson K, Lindblad M, Ekman
S, Johansson J, Lundell L, Ndegwa N, Hedberg J and Nilsson M:
Association between time interval from neoadjuvant
chemoradiotherapy to surgery and complete histological tumor
response in esophageal and gastroesophageal junction cancer: A
national cohort study. Dis Esophagus. 33:doz0782020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van der Werf LR, Dikken JL, van der Willik
EM, van Berge Henegouwen MI and Nieuwenhuijzen GAP: Time interval
between neoadjuvant chemoradiotherapy and surgery for oesophageal
or junctional cancer: A nationwide study. Eur J Cancer. 91:76–85.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azab B, Amundson JR, Picado O, Ripat C,
Macedo FI, Franceschi D, Livingstone AS and Yakoub D: Impact of
chemoradiation-to-surgery interval on pathological complete
response and short- and long-term overall survival in esophageal
cancer patients. Ann Surg Oncol. 26:861–868. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raman V, Jawitz OK, Voigt SL, Yang CJ,
Wang H, Harpole DH and D'Amico TA: Effect of time to surgery on
outcomes in stage I esophageal adenocarcinoma. J Thorac Cardiovasc
Surg. 159:1626–1635.e1. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et
al: Esophageal and esophagogastric junction cancers, version
2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr
Canc Netw. 17:855–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp
HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg
H, et al: Histopathological regression after neoadjuvant docetaxel,
oxaliplatin, fluorouracil, and leucovorin versus epirubicin,
cisplatin, and fluorouracil or capecitabine in patients with
resectable gastric or gastro-oesophageal junction adenocarcinoma
(FLOT4-AIO): Results from the phase 2 part of a multicentre,
open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Amico TA: Mckeown esophagogastrectomy. J
Thorac Dis. 6 (Suppl 3):S322–S324. 2014.PubMed/NCBI
|
|
24
|
Jung MK, Schmidt T, Chon SH, Chevallay M,
Berlth F, Akiyama J, Gutschow CA and Mönig SP: Current surgical
treatment standards for esophageal and esophagogastric junction
cancer. Ann N Y Acad Sci. 1482:77–84. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ryu HS, Lee JL, Kim CW, Yoon YS, Park IJ,
Lim SB, Yu CS, Kim JH and Kim JC: Correlative significance of tumor
regression grade and ypT category in patients undergoing
preoperative chemoradiotherapy for locally advanced rectal cancer.
Clin Colorectal Cancer. 21:212–219. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HS, Choi DH, Park HC, Park W, Yu JI
and Chung K: Correlation between tumor regression grade and rectal
volume in neoadjuvant concurrent chemoradiotherapy for rectal
cancer. Radiat Oncol J. 34:186–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chao YK, Chang CB, Chuang WY, Wen YW,
Chang HK, Tseng CK, Yeh CJ and Liu YH: Correlation between tumor
regression grade and clinicopathological parameters in patients
with squamous cell carcinoma of the esophagus Who received
neoadjuvant chemoradiotherapy. Medicine (Baltimore). 94:e14072015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Furukawa T, Hamai Y, Hihara J, Emi M,
Yamakita I, Ibuki Y, Kurokawa T and Okada M: Impact of interval
between neoadjuvant chemoradiation and surgery upon morbidity and
survival of patients with squamous cell carcinoma of thoracic
esophagus. Anticancer Res. 38:5239–5245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen K, Yu S, Zhang Z, Zhang Y, Li W, Kang
M and Lin Y: Investigation and analysis of influencing factors of
early activity compliance of patients after minimally invasive
esophagectomy. Ann Palliat Med. 10:12657–12663. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie SH, Santoni G, Malberg K, Lagergren P
and Lagergren J: Prediction model of long-term survival after
esophageal cancer surgery. Ann Surg. 273:933–939. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Turgeman I and Ben-Aharon I: Evolving
treatment paradigms in esophageal cancer. Ann Transl Med.
9:9032021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sukocheva OA, Li B, Due SL, Hussey DJ and
Watson DI: Androgens and esophageal cancer: What do we know? World
J Gastroenterol. 21:6146–6156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jarosz-Biej M, Smolarczyk R, Cichoń T and
Kułach N: Tumor microenvironment as a ‘game changer’ in cancer
radiotherapy. Int J Mol Sci. 20:32122019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haisley KR, Laird AE, Nabavizadeh N,
Gatter KM, Holland JM, Vaccaro GM, Thomas CR Jr, Schipper PH,
Hunter JG and Dolan JP: Association of intervals between
neoadjuvant chemoradiation and surgical resection with pathologic
complete response and survival in patients with esophageal cancer.
JAMA Surg. 151:e1627432016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tirumani H, Rosenthal MH, Tirumani SH,
Shinagare AB, Krajewski KM and Ramaiya NH: Esophageal carcinoma:
Current concepts in the role of imaging in staging and management.
Can Assoc Radiol J. 66:130–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
